Trial Profile
A retrospective, single-center, cohort study analysing the effect of Subtilisin/Kexin Type 9 (PCSK9) inhibition on sterol absorption with evolocumab and alirocumab therapy in real world patients
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 16 Jan 2020
Price :
$35
*
At a glance
- Drugs Alirocumab (Primary) ; Evolocumab (Primary)
- Indications Hypercholesterolaemia
- Focus Pharmacodynamics
- 06 Jul 2017 New trial record